Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) shares were up 24.1% on Wednesday . The company traded as high as C$1.72 and last traded at C$1.70. Approximately 892,106 shares changed hands during mid-day trading, an increase of 556% from the average daily volume of 135,968 shares. The stock had previously closed at C$1.37.
Wall Street Analysts Forecast Growth
Separately, Jones Trading downgraded Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th.
Get Our Latest Stock Report on ONC
Oncolytics Biotech Trading Down 3.7%
The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The stock has a market cap of C$119.46 million, a P/E ratio of -4.32 and a beta of 1.35. The stock's fifty day moving average is C$0.79 and its 200 day moving average is C$0.94.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Further Reading
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
